R

Retina Centre of Ottawa | Ottawa, Canada

Research site
(Unclaimed)
Location
2211 Carling Avenue, Ottawa, Ontario, Canada
Site insights

Top conditions

Macular Degeneration (5 trials)

Atrophy (4 trials)

Geographic Atrophy (4 trials)

Retinal Vein Occlusion (1 trial)

Macular Edema (1 trial)

Top treatments

APL-2
Zimura
Dexamethasone
Pegcetacoplan
Avacincaptad pegol
IBE-814

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 6
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary effi...

Active, not recruiting
Diabetic Macular Oedema
Retinal Vein Occlusion With Macular Oedema
Drug: IBE-814 70ug
Drug: IBE-814 140ug

Trial sponsors

A

Apellis Pharmaceuticals (2 trials)

AbbVie logo

AbbVie (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems